ZNTL
Zentalis Pharmaceuticals, Inc.
There isn't enough reported data to score ZNTL yet.
ZNTL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ZNTL's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
ZNTL PE Valuation
ZNTL has no meaningful PE right now: it lost money over the past year.
ZNTL Forward outlook
There aren't enough analyst estimates for ZNTL to show an outlook.
ZNTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.93 | +$0.15 |
| Q2 2026 | -$1.96 | +$0.31 |
| Q1 2026 | -$1.74 | +$1.40 |
| Q4 2025 | -$1.91 | +$0.42 |
| Q3 2025 | -$2.08 | +$0.34 |
| Q2 2025 | -$2.27 | +$0.38 |
| Q1 2025 | -$3.14 | +$0.12 |
| Q4 2024 | -$2.33 | +$2.14 |
ZNTL is still losing money, but far less than before: $1.93 per share over the past year, against $5.58 at its worst in late 2020.
ZNTL Quarterly Revenue
ZNTL's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -186% | N/A |
| Q1 2024 | -61% | N/A |
ZNTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$32.7M | -$5.7M |
| Q2 2026 | -$37.2M | -$2.5M |
| Q1 2026 | -$33M | -$354K |
| Q4 2025 | -$30.9M | +$8.8M |
| Q3 2025 | -$27M | +$17.1M |
| Q2 2025 | -$34.7M | +$612K |
| Q1 2025 | -$32.6M | +$19.4M |
| Q4 2024 | -$39.7M | +$1.1M |
ZNTL has burned cash in almost every quarter: −$134M over the past year, against −$134M the year before.
ZNTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +13.3M shares |
| 1 year | +17% | +12.5M shares |
| 3 years | +20% | +14M shares |
| 5 years | +90% | +40M shares |
| Available history | +145% | +50.1M shares |
ZNTL has 85M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
ZNTL Net Leverage
ZNTL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ZNTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 2.5 | Oversold |
ZNTL's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
ZNTL PE vs Healthcare Sector
ZNTL has no meaningful PE right now: it lost money over the past year.
ZNTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.19 | 23% below |
| 20 week MA | $3.35 | 50% below |
| 50 week MA | $3.18 | 47% below |
| 100 week MA | $2.43 | 31% below |
| 200 week MA | $8.53 | 80% below |
ZNTL is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
ZNTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.2 | $57.2 | +147% |
| 2021 | $57.2 | $84.0 | +47% |
| 2022 | $84.0 | $18.3 | -78% |
| 2023 | $18.3 | $15.2 | -17% |
| 2024 | $15.2 | $3.06 | -80% |
| 2025 | $3.06 | $1.36 | -56% |
| 2026 YTD | $1.36 | $1.68 | +24% |
ZNTL has finished four years in a row lower, and it's up 24% so far in 2026.